P-Selectin as Predictor Venous Thromboembolism in Cancer Patients Undergoing Chemotherapy

Hiroshima Journal of Medical Sciences Volume 67 Page 15-20 published_at 2018-05
アクセス数 : 946
ダウンロード数 : 164

今月のアクセス数 : 8
今月のダウンロード数 : 0
File
HiroshimaJMedSci_67s_15.pdf 238 KB 種類 : fulltext
Title ( eng )
P-Selectin as Predictor Venous Thromboembolism in Cancer Patients Undergoing Chemotherapy
Creator
Suharti C.
Santosa
Pangarso Eko Adhi
Setiawan Budi
Samakto Baringin de
Source Title
Hiroshima Journal of Medical Sciences
Volume 67
Start Page 15
End Page 20
Journal Identifire
[PISSN] 0018-2052
[EISSN] 2433-7668
[NCID] AA00664312
Abstract
Background: Venous thromboembolism (VTE), consisting of deep vein thrombosis (DVT) and pulmonary embolism (PE), is the second-leading cause of death in patients with malignancy. P-selectin, the member of the selectin family of cell adhesion molecules, is found in the alpha granules of platelets and the Weibel-Palade bodies of endothelial cells. It is express on the cell surface on activation, mediates the adhesion of leukocytes, platelets, and cancer cells in inflammation, thrombosis, and cancer growth and metastasis. Recently, P-selectin has been investigated as a novel predictor for DVT. Objectives: To investigate the role of sP-selectin as predictors of DVT in cancer patients undergoing chemotherapy. Patients and Methods: This prospective cohort study was conducted in Dr. Kariadi hospital, Semarang, Indonesia, on 40 newly diagnosed cancer patients. Venous blood samples were drawn prior and after initial chemotherapy, for sP-selectin measurement with ELISA method. These patients were observed for the possibility of developing VTE during three-months period. Results: DVT occurred in 5 (12.5%) patients after a median period of 8 weeks. The most frequent cancer type was colorectal cancer (45%) and cervical cancer (15%). The cut-off point sP-selectin pre-and post- chemotherapy were 106,7 ng/ml and 111,7 ng/ml respectively. The median levels of sP-selectin in DVT patients pre-chemotherapy was 121.0ng/ml (IQR 107.5-230.6) and post-chemotherapy was 204.4ng/ml (IQR 110.9-278.3). In other hand, the median levels of sP- selectin pre-chemotherapy and post- chemotherapy in DVT negative patients were 82.0ng/ml (IQR 31.3-230.6) and 92.5 (IQR 40.9-278.3), respectively. With cut-off point sP-selectin level 111,7 ng/ml, the relative risk of DVT event was 8,7 (95% CI 1,017-74,39). Conclusion: In this study, high plasma levels of s P-selectin are predictive for venous thromboembolism in cancer patients undergoing chemotherapy.
Keywords
venous thromboembolism
sP-selectin
cancer
chemotherapy
NDC
Medical sciences [ 490 ]
Language
eng
Resource Type departmental bulletin paper
Publisher
Hiroshima University Medical Press
Date of Issued 2018-05
Rights
Copyright (c) 2018 Hiroshima University Medical Press
Publish Type Version of Record
Access Rights open access
Source Identifier
[ISSN] 0018-2052
[NCID] AA00664312